Why carry out this study?

- Many patients undergoing transcather aortic valve replacement (TAVR) have an indication for anticoagulation.
- The optimal antithrombotic strategy in these patients has not been well studied.
- Our study asks what is the current practice of antithrombotic therapy following TAVR at a single, large academic institution.

What was learned from the study?

- Antithrombotic therapy following TAVR is highly variable.
- Almost two-thirds of patients after TAVR have an indication for anticoagulation.
- Most patients at our institution with an indication for anticoagulation are discharged on aspirin and warfarin.

This summary slide represents the opinions of the authors. No funding or sponsorship was received for this study or publication of this article. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).

